Published in Proc Natl Acad Sci U S A on January 23, 2006
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol (2010) 6.28
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science (2013) 3.33
Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A (2009) 2.85
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A (2009) 2.72
Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell (2011) 2.50
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget (2010) 2.44
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal (2008) 2.19
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J (2007) 1.74
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol (2013) 1.66
RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell (2013) 1.60
Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci (2010) 1.58
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol (2009) 1.47
Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A (2010) 1.40
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther (2009) 1.34
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev (2009) 1.32
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol (2011) 1.28
A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2010) 1.23
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol (2008) 1.20
Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol (2012) 1.17
Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci U S A (2009) 1.17
The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol (2010) 1.16
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res (2010) 1.10
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood (2008) 1.09
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther (2010) 1.08
Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc Natl Acad Sci U S A (2013) 1.06
Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat (2008) 1.06
Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol Regul (2012) 1.05
Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res (2012) 1.03
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
A beta version of life: p110β takes center stage. Oncotarget (2010) 1.01
Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98
Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. Proc Natl Acad Sci U S A (2007) 0.98
3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. Cancer Manag Res (2013) 0.96
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci (2015) 0.92
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
New molecular targets in mantle cell lymphoma. Semin Cancer Biol (2011) 0.92
Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells. Int J Biol Sci (2015) 0.92
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome. J Allergy Clin Immunol (2014) 0.92
miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. Carcinogenesis (2012) 0.91
Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins. Biochem J (2007) 0.91
PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts. Cell Death Differ (2009) 0.90
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol (2013) 0.89
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Distinct roles for isoforms of the catalytic subunit of class-IA PI3K in the regulation of behaviour of murine embryonic stem cells. J Cell Sci (2009) 0.86
Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase. PLoS One (2013) 0.86
Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol (2012) 0.86
The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice. Am J Physiol Lung Cell Mol Physiol (2012) 0.86
Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res (2009) 0.86
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget (2015) 0.84
Targeting PI3K in neuroblastoma. J Cancer Res Clin Oncol (2010) 0.83
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov (2016) 0.83
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med (2010) 0.83
Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs. Proc Natl Acad Sci U S A (2015) 0.83
Targeting the PI3K pathway for cancer therapy. Future Med Chem (2012) 0.82
PI3K enters beta-testing. Cell Metab (2008) 0.82
Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity. PLoS One (2013) 0.81
The role of phosphoinositide-regulated actin reorganization in chemotaxis and cell migration. Br J Pharmacol (2014) 0.80
Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase. Trends Pharmacol Sci (2013) 0.80
Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol (2014) 0.80
PI-3 kinase p110β: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol (2014) 0.80
The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. PLoS One (2015) 0.78
Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer J (2014) 0.78
PI3Kβ downstream of GPCRs - crucial partners in oncogenesis. Oncotarget (2012) 0.77
PI3King the right partner: unique interactions and signaling by p110β. Postdoc J (2015) 0.76
p84 forms a negative regulatory complex with p110γ to control PI3Kγ signalling during cell migration. Immunol Cell Biol (2015) 0.75
Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol (2014) 0.75
E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing. Oncotarget (2016) 0.75
Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. J Allergy Clin Immunol (2016) 0.75
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget (2017) 0.75
Novel PI3Kγ mutation in a 44-year-old man with chronic infections and chronic pelvic pain. PLoS One (2013) 0.75
INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC. Mol Cancer Res (2017) 0.75
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol (1984) 8.63
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79
Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci (1997) 4.52
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J (1996) 3.99
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
Characteristics of two new avian tumor virus subgroups. Virology (1969) 3.81
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell (1986) 3.70
Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47
PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J (1994) 3.39
P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A (1997) 3.09
The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell (1997) 3.03
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A (1998) 2.99
Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta (1998) 2.88
ATM-related genes: what do they tell us about functions of the human gene? Cell (1995) 2.65
Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev (1990) 2.46
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol (2002) 2.42
p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem (1997) 2.37
Phosphoinositide 3-kinase signalling--which way to target? Trends Pharmacol Sci (2003) 2.35
When is a lipid kinase not a lipid kinase? When it is a protein kinase. Cell (1995) 2.19
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev (2005) 2.18
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J Biol Chem (1994) 2.09
Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol (2002) 2.03
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat Cell Biol (2005) 2.00
Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. Science (1998) 1.89
Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem (1999) 1.78
Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem (1998) 1.74
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem (2000) 1.71
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol (2003) 1.57
A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. J Biol Chem (2000) 1.56
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res (2003) 1.51
Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res (2003) 1.47
Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases. Biochem J (2000) 1.44
Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J (1988) 1.41
Phosphatidylinositol 3-kinase gamma mediates shear stress-dependent activation of JNK in endothelial cells. Am J Physiol (1998) 1.27
Insulin receptor substrate 1 is phosphorylated by the serine kinase activity of phosphatidylinositol 3-kinase. Biochem J (1994) 1.26
Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem (2002) 1.23
Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO J (1999) 1.19
Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16
Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem (2001) 1.11
Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor. J Biol Chem (2000) 1.09
Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo. Mol Cell Biol (2004) 1.05
Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem (2002) 1.04
Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem (2005) 1.04
Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms. Protein Expr Purif (2004) 1.03
Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin. Biochem J (1997) 0.97
Expression of c-MYC under the control of GATA-1 regulatory sequences causes erythroleukemia in transgenic mice. J Exp Med (1995) 0.95
eIF4E binding protein 1 and H-Ras are novel substrates for the protein kinase activity of class-I phosphoinositide 3-kinase. Biochem Biophys Res Commun (2004) 0.93
Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell Motil Cytoskeleton (2004) 0.91
Differential regulation of lipid and protein kinase activities of phosphoinositide 3-kinase gamma in vitro. Biol Chem (1999) 0.90
Retinoic acid induces selective expression of phosphoinositide 3-kinase gamma in myelomonocytic U937 cells. Cell Growth Differ (1999) 0.89
Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. Arch Biochem Biophys (2003) 0.89
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A (2008) 2.81
Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature (2004) 2.73
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood (2005) 2.35
Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol (2006) 2.29
Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med (2008) 2.25
Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A (2004) 2.19
The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal (2010) 2.15
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A (2007) 1.98
PI3Kβ plays a critical role in neutrophil activation by immune complexes. Sci Signal (2011) 1.95
The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol (2012) 1.94
Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol (2004) 1.81
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology (2010) 1.80
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol (2009) 1.77
Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc (2009) 1.72
The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol (2006) 1.70
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67
Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci (2009) 1.65
Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res (2005) 1.59
Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab (2009) 1.59
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res (2003) 1.51
The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J (2007) 1.48
PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood (2014) 1.48
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther (2011) 1.41
Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A (2010) 1.40
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci (2008) 1.39
Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol (2007) 1.38
Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol (2005) 1.37
Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer (2009) 1.36
The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med (2008) 1.34
Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol (2008) 1.31
The PI3K p110alpha isoform regulates endothelial adherens junctions via Pyk2 and Rac1. J Cell Biol (2010) 1.28
Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood (2007) 1.27
100 years of Rous sarcoma virus. J Exp Med (2011) 1.24
Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics (2007) 1.24
Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol (2007) 1.23
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol (2005) 1.20
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol Cell Proteomics (2005) 1.20
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal (2013) 1.20
Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS One (2007) 1.18
Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17
PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol (2010) 1.16
Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16
Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. Oncogene (2003) 1.16
Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J (2007) 1.14
CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood (2009) 1.14
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J Immunol (2009) 1.12
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood (2010) 1.12
Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem (2003) 1.11
Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle (2010) 1.11
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett (2009) 1.11
PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun (2011) 1.10
Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A (2003) 1.09
Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J (2002) 1.06
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res (2009) 1.06
Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol (2013) 1.04
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J (2012) 1.03
Phosphoinositide 3-kinase δ regulates membrane fission of Golgi carriers for selective cytokine secretion. J Cell Biol (2010) 1.03
Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med (2013) 1.01
Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci U S A (2004) 1.01
The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells. Blood (2006) 1.00
Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse. Cell Signal (2012) 1.00
Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol (2008) 1.00
Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol (2006) 1.00
Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics (2012) 0.99
Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells. J Cell Sci (2010) 0.99
Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells. Nat Commun (2011) 0.99
Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci U S A (2006) 0.98
Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148. Mol Biol Cell (2011) 0.97
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med (2013) 0.97
MafA has strong cell transforming ability but is a weak transactivator. Oncogene (2003) 0.96
Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene (2003) 0.96
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep (2008) 0.95
Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res (2004) 0.95
PI3K regulatory subunits lose control in cancer. Cancer Cell (2009) 0.95
Regulation of p110delta PI 3-kinase gene expression. PLoS One (2009) 0.95
Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene (2002) 0.94
An essential role for protein synthesis in oncogenic cellular transformation. Oncogene (2004) 0.94
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. J Am Chem Soc (2009) 0.93